Granules India Ltd

- Yes, Granules India Limited has ongoing and planned capital expenditure (CAPEX) primarily for capacity expansion in finished dosage (FD), active pharmaceutical ingredients (API), and enzyme technology platforms, indicating potential future fundraising needs. - Rs. 1,444 million CAPEX was spent in Q1 FY25, mainly in Granules Life Sciences. - The company is cautious about large investments like the Rs. 2,000 crore CAPEX for backward integration projects, with a stage-gate approach before committing further funds. - No specific mention of immediate new debt or equity fundraising in the call. - Net debt decreased by Rs. 481 million in Q1 FY25 to Rs. 7,941 million, showing some debt reduction. - Management indicated alignment of CAPEX plans with estimates and capital expenditure expectations, implying monitoring fundraising aligned with project needs.

- Ongoing capacity expansion in finished dosage (FD), API, and enzyme technology platforms to support growth. - New oncology API manufacturing facility and augmentation of finished dosage and infrastructure planned; project execution starting September 2024, expected to take ~12 months. - Enzyme manufacturing infrastructure and chemical steps investments finalized; execution to begin Q3 FY25, expected completion in 14-18 months. - Granules Life Sciences facility at Genome Valley recently operational with 2 billion capacity; validation ongoing. - Rs. 2,000 crore CAPEX planned for CZRO project (DCDA and PAP plants) with cautious, stage-gated investment approach; infrastructure delays impacting timelines. - Focused on backward integration for APIs despite current low prices, considering future global supply and sustainability benefits. - R&D spend increased (Rs. 62 crores in the recent quarter) with plans for further increase to support innovation and new product launches.

- Oncology product launches expected from FY26, starting in select geographies with early approvals (Page 16). - Diabetes innovative products focusing on Metformin derivatives like gliflozins and Gliptins; aiming to be a significant player in this segment (Page 16). - North America sales are growing robustly, with expectations of over 20% growth moving forward, driven by formulations and new product launches (Pages 14-15). - European business currently down due to paracetamol inventory build-up but expected to stabilize and grow with increased formulations and API sales from next year (Pages 8-9, 14). - Focus on increasing finished dosage (FD) contribution, currently at 76%, expected to maintain or grow further as launches continue (Pages 7-8, 14). - Overall revenue growth driven by formulations; API and PFI segments expected to decline as internal consumption for formulations increases (Page 8). - New geographic markets such as South Africa and Asian countries targeted for future growth (Page 9).

- Granules India expects continued growth driven primarily by the formulations (FD) segment, which now contributes 76% of total sales and is likely to grow further through new product launches and geographic expansions, especially in the US. - EBITDA margins are expected to improve gradually, with a target to remain above 20% and inch closer to or above 22% in FY25 due to value-added formulations and operational efficiencies. - Revenue growth in North America is projected to continue at 20%+ driven by formulations, with European business expected to stabilize and improve as API and formulation sales ramp up. - Paracetamol API sales, which have been low and impacted by price erosion, are anticipated to stabilize and see growth from late FY25 or early FY26. - Operating costs, including employee expenses, are expected to grow at a slower rate than revenues in FY25, improving profitability. - Overall, Granules aims for steady earnings growth with improving operating leverage and expansion in margin profile over the medium term.

The provided transcript/pages do not contain specific details about Granules India Limited's current or expected order book or pending orders. The discussion mainly revolves around: - Revenue growth and product mix. - Stabilization of price erosion in the US business. - Growth outlook for North America and Europe. - Contribution and growth of Finished Dosage (FD) formulations. - Paracetamol API market challenges and recovery timeline. - Increased focus on R&D, new product launches, and expanding formulation sales. - Strategic emphasis on backward integration and sustainable margins. No explicit quantitative or qualitative data on order book or pending orders are mentioned.